Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
endocrine system diseases | D004700 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
thyroid neoplasms | EFO_0003841 | D013964 | — |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Vandetanib, Caprelsa, Genzyme Corp | |||
8067427 | 2028-08-08 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 4 | 2 | 1 | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 6 | 9 | 4 | — | — | 19 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 6 | 2 | — | — | 11 |
Papillary thyroid cancer | D000077273 | — | — | 4 | 4 | 3 | — | 2 | 10 |
Medullary thyroid cancer | — | — | — | 1 | — | 3 | — | 1 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 7 | 5 | — | — | 1 | 13 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 7 | — | — | — | 9 |
Colorectal neoplasms | D015179 | — | — | 5 | 1 | — | — | — | 6 |
Prostatic neoplasms | D011471 | — | C61 | 1 | 4 | — | — | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 4 | 2 | — | — | — | 5 |
Gliosarcoma | D018316 | — | — | 3 | 2 | — | — | — | 4 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 3 | — | — | — | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 3 |
Head and neck neoplasms | D006258 | — | — | 2 | 1 | — | — | — | 3 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma | D000230 | — | — | 3 | — | — | — | — | 3 |
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Esophageal neoplasms | D004938 | — | C15 | 2 | — | — | — | — | 2 |
Glioma | D005910 | EFO_0000520 | — | 2 | — | — | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | — | — | — | — | 1 |
Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | — | — | — | — | 1 |
Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
Drug common name | Vandetanib |
INN | vandetanib |
Description | Vandetanib is a quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is an aromatic ether, a secondary amine, a member of quinazolines, a member of piperidines, an organobromine compound and an organofluorine compound. |
Classification | Small molecule |
Drug class | angiogenesis inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1 |
PDB | — |
CAS-ID | 443913-73-3 |
RxCUI | — |
ChEMBL ID | CHEMBL24828 |
ChEBI ID | 49960 |
PubChem CID | 3081361 |
DrugBank | DB08764 |
UNII ID | YO460OQ37K (ChemIDplus, GSRS) |